The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2023 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
    • Research Competitions
      • Research Competition Winners
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Guide to “Coronavirus in the Crosshairs”

Guide to “Coronavirus in the Crosshairs”

Coronavirus in the Crosshairs

An urgent and immediate need for knowledge about COVID-19 and for vaccines and drugs to inhibit the virus and treat symptoms has existed since the disease started to spread in December 2019. In this series of posts, The Antibody Society examines the ongoing discovery and development of COVID-19 interventions for broad use, including small molecule and biologic drugs, and vaccines.

Part 1 [March 20, 2020]

In the first installment of the series, we discuss ongoing or planned clinical trials of small molecule drugs remdesivir, hydroxy chloroquine, chloroquine, lopinavir-ritonavir and favipiravir.

Part 2: Vaccines in development [March 23, 2020]

In this installment of the series, we discuss vaccines in preclinical and clinical development, including mRNA-1273, Ad5-nCoV and other vaccine candidate

Part 3: Antibodies from human plasma [March 25, 2020]

In Part 3 of the series, we focus on the use of natural antibodies, i.e., anti-SARS-CoV-2 polyclonal antibodies found in convalescent plasma, in treating COVID-19. In the current emergency when time is of the essence, medical professionals are applying the century-old knowledge that antibody-rich plasma derived from blood donated by people who have recovered from a disease may aid other patients. The efficacy of convalescent plasma was studied in outbreaks of other respiratory infections, including the 2009-2010 H1N1 influenza virus pandemic, 2003 SARS-CoV-1 epidemic, and the 2012 MERS-CoV epidemic.

Part 4: Antibody therapeutics [March 29, 2020]

In Part 4 of the series, we provide details about re-purposed biologics, such as monoclonal antibodies (mAbs) that are marketed or in clinical studies for other indications, that might ameliorate COVID-19 symptoms and that are already in clinicals studies of COVID-19 patients. mAbs discussed include:

  • Anti-IL-6R mAbs tocilizumab (Actemra®) and sarilumab (Kevara®).
  • Anti-IL-6 siltuximab (SYLVANT®)
  • Anti-GM-CSF mAbs (TJ003234, Gimsilumab, Lenzilumab, Otilimab and Namilumab

We also discuss anti-SARS-CoV-2 antibodies that are in preclinical development and may enter clinical study by the end of 2020.

Part 5: Harnessing the human immune system [April 9, 2020]

In this installment of the “Coronavirus in the crosshairs” series, The Antibody Society provides updates on the status of:

  • Anti-SARS-CoV-2 antibody (serological) tests
  • Plasma-based therapeutics
  • Vaccines

Part 6: Web Resources [April 13, 2020]

In Part 6 of our series “Coronavirus in the crosshairs“, we provide links to a sampling of websites that collectively offer extensive, and free, coverage of the COVID-19 pandemic.
Content includes:

  • Global Distribution of SARS-CoV-2
  • COVID-19 Clinical Studies
  • Therapeutics and Vaccines in Development
  • Scientific and Medical Literature

Part 7: Diagnostic tests [April 28, 2020]

The coronavirus SARS-CoV-2 triggers a lethal and highly infectious disease, COVID-19, so rapid (minutes-to-hour) point-of-care tests are essential to reduce spread and establish the epidemiology of infection.
This installment of the series discusses:

  • Classes of virus tests
  • Viral RNA detection
  • Viral antigen detection
  • Detecting anti-viral serological responses
  • Deciphering test results

Part 8: FDA’s Emergency Use Authorization of Therapeutics [May 13, 2020]

During public health emergencies, the U.S. Food and Drug Administration (FDA) can allow use of unapproved medical products or unapproved uses of approved medical products to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by threat agents, such as SARS-CoV-2, when there are no adequate, approved, and available alternatives.
This installment of the series discusses:

  • Letters of authorization issued for therapeutics and
  • Possible biologic candidates for EUAs in 2020.

Part 9: Anti-SARS-CoV-2 biologics entering clinical study [May 28, 2020]

As of the end of May 2020, more than 15 organizations have announced that their anti-SARS-CoV-2 molecules may enter clinical study during June to December 2020. This installment of the series includes:
• Name of organization and partners
• Type of molecule (mostly antibody, but also DARPin and fusion proteins)
• Estimated timing of the start of clinical studies

A comparison of approval success rates for anti-infective antibodies vs. all antibody therapeutics is also included.

 

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • FDA approves Zynyz™ (retifanlimab-dlwr) for Merkel cell carcinoma March 23, 2023
  • Ultralong CDR H3-based knobs: the smallest antibody fragment March 6, 2023
  • TRUST4 is now certified as AIRR-compliant March 1, 2023

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals